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radiotherapy can manipulate these and speculate on the 
application of radio-immunotherapy in the control of cancer. 
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Purpose/Objective:Despite therapeutic advances in 
radiotherapy, the control of metastasis, is still a major 
challenge in cancer management. In order to develop more 
efficient therapies to counteract cancer cell invasion and 
metastasis, we need to understand the contribution of the 
tumour microenvironment. We are particularly interested on 
the effect of radiotherapy on macrophage behavior and how 
irradiated macrophages may modulate cancer cell activities 
and their response to radiotherapy. 
Materials and Methods: In order to address this question, we 
subjected primary human monocyte-derived macrophages to 
conventional doses of ionizing radiation, as used for cancer 
patient's treatment, and characterized macrophage 
functionality. The impact of irradiated macrophages on 
cancer cell activities, namely invasion and motility was also 
investigated, through Matrigel-invasion assay and time-lapse 
microscopy, respectively. 
Results: Our results evidence that radiation induces 
macrophage DNA damage, through H2AX-phosphorylation, 
without causing apoptosis. Instead, the increased expression 
of the anti-apoptotic protein Bcl-xL may contribute to 
irradiated macrophage pro-survival activity. Together, 
macrophage MMP-2 and 9 activities are not affected by 
ionizing radiation. Finally, we are also focused on the effect 
of ionizing radiation on macrophage proteome. Different 
proteomic approaches revealed that irradiated macrophages 
present altered expression levels of some metabolism-related 
proteins, which are currently under investigation. 
Nevertheless, irradiated macrophages are still able to 
promote cancer cell invasion and its conditioned medium 
increases motility of cancer cells.  
Conclusions: In summary, our results demonstrate that 
although the ionizing radiation doses used in the present 
work induce DNA damage, macrophages are still functional. 
In fact, irradiated macrophages are still able to promote 
cancer cell activities, namely invasion and motility. Current 
research on identification of cytokines and chemokines 
differentially expressed in macrophages upon ionizing 
radiation will complement these findings. Furthermore, this 
work will allow a better understanding on how ionizing 
radiation affects macrophage-cancer cell communication, 
opening perspectives for new therapeutic strategies that 
could be coupled with radiotherapy. 
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Purpose/Objective: The gastrin-releasing peptide 
receptors(GRPR) are up-regulated in many cancers, including 
prostate, colon, gastric, breast, pancreatic, and small cell 
lung cancers. Because bombesin binds to GRPR with high 
affinity, bombesin analogues have been labeled with various 
radionuclides for a targeted radiotherapy. The present study 
describes a new radiolabeled bombesin analogue for 
treatment of GRPR-overexpressing prostate tumors. 
Materials and Methods: A novel peptide was synthesized 
using a solid-phase synthetic method, and radiolabeled with 
177Lu, which was produced by the HANARO research reactor 
(thermal neutron flux of 1.8 × 1014 n·cm-2·s-1). The 
pharmacokinetic characteristics and therapeutic efficacy of 
the radiolabeled peptide were evaluated using PC-3 human 
prostate carcinoma cells-xenografted mice. 
Results: The purity of the synthesized peptide was exceeded 
98%, and it was radiolabeled with 177Lu at a high 
radiochemical purity (> 98%). The radiolabeled peptide 
showed in vitro nanomolar binding affinity on GRPR. It was 
highly accumulated in PC-3 tumors in vivo, and rapidly 
excreted from the blood pool. As a result, PC-3 tumor was 
specifically visualized by SPECT/CT imaging at 1 hr p.i. (Fig. 
1.). In addition, the radiolabeled peptide significantly 
inhibited the PC-3 tumor growth (P < 0.05) without 
treatment-related toxicities, except for slight 
glomerulopathy. 
 
 
Fig. 1. SPECT/CT images of PC-3-bearing mice using 177Lu-
labeled bombesin analogue. 
Conclusions: The pharmacokinetic, imaging, and therapy 
studies suggest that a novel 177Lu-labeled peptide has a 
promising characteristics for the targeted radiotherapy of 
GRPR-overexpressing prostate tumors.  
 
 
